Pérez Cano R, Moruno R, Montoya M J, Vazquez M A, Galán F, Garrido M
Department of Medicine, University of Seville, Spain.
Clin Rheumatol. 1989 Jun;8 Suppl 2:56-60. doi: 10.1007/BF02207235.
Estrogens retard bone loss after menopause and constitute the most logical therapy for the prevention of postmenopausal osteoporosis. Estrogens are contraindicated in some circumstances and some postmenopausal women are unwilling to accept them. We have used ADFR therapy as an alternative in the prevention of postmenopausal bone loss. One hundred women in the early postmenopausal period (6-24 months since the last menses) were introduced into the study. 50 were treated with placebo and 50 were treated with ADFR therapy (phosphorus 1.5 gr/day during 3 days, followed by SCT 100 UI/day during 10 days and calcium 1 gr/day). After 77 days without any therapy we repeated the cycles every 3 months. Bone mass was evaluated at the beginning and at 3, 6, 12 and 18 months by dualphoton absorptionmetry lumbar spine. In the control group, the mean spinal BMD decreased 7.31% after 12 months and 6.16% after 18 months (p greater than 0.05). The ADFR group only had a mean spinal BMD decrease of 3.79% and 1.1% after 12 and 18 months respectively (NS). Bone loss was greater in control than in ADFR group after 12 and 18 months (p less than 0.05 at both times). We conclude that phosphorus and calcitonin like ADFR therapy may be a useful alternative to estrogen for the prevention of accelerated bone loss after menopause.
雌激素可延缓绝经后的骨质流失，是预防绝经后骨质疏松症最合理的治疗方法。在某些情况下，雌激素是禁忌的，一些绝经后女性也不愿意接受雌激素治疗。我们已将ADFR疗法作为预防绝经后骨质流失的替代方法。100名处于绝经后早期（自末次月经起6 - 24个月）的女性被纳入研究。50名接受安慰剂治疗，50名接受ADFR疗法（3天内每日服用磷1.5克，随后10天内每日服用鲑鱼降钙素100国际单位，每日服用钙1克）。在77天不进行任何治疗后，我们每3个月重复一次疗程。通过双能光子吸收法测量腰椎骨量，在开始时以及3、6、12和18个月时进行评估。在对照组中，12个月后脊柱骨密度平均下降7.31%，18个月后下降6.16%（p大于0.05）。ADFR组在12个月和18个月后脊柱骨密度平均分别仅下降3.79%和1.1%（无统计学意义）。12个月和18个月后，对照组的骨质流失大于ADFR组（两次均p小于0.05）。我们得出结论，像ADFR疗法中的磷和降钙素可能是雌激素的一种有用替代方法，用于预防绝经后加速的骨质流失。
